3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase NA
1
Status
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
10
Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Pain, Postoperative
3
Neurotoxicity Syndromes
3
Melanoma
3
Leukemia, Myeloid, Acute
3
Brain Neoplasms
3
Recurrence
2
Ovarian Neoplasms
2
Hemorrhage
2
Chronic Pain
2
Agnosia
2
Vulvodynia
1
Uterine Cervical Neoplasms
1
Stomatitis
1
Stomach Neoplasms
1
Spinal Cord Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Seizures
1
Radiodermatitis
1
Radiation Injuries
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Postoperative Complications
1
Peripheral Nervous System Diseases
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Parathyroid Neoplasms
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Interventions
Dexamethasone
28
Rituximab
16
pomalidomide
13
Gemcitabine
12
Lenalidomide
11
Cisplatin
11
Bortezomib
11
Paclitaxel
10
Cyclophosphamide
8
Carboplatin
8
carfilzomib
7
selinexor
5
daratumumab
5
Drug Therapy
5
Doxorubicin
5
Cytarabine
5
ibrutinib
4
Vincristine
4
Temozolomide
4
Prednisone
4
Docetaxel
4
Calcium Dobesilate
4
Bevacizumab
4
Aspirin
4
tisagenlecleucel
3
Cetuximab
3
Bendamustine Hydrochloride
3
venetoclax
2
ofatumumab
2
galiximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Recurrence
×
Sodium Chloride
×
Clear all
NCT05899465
2025-03-18
PRIME
University of Aarhus
Phase 3
Recruiting
1,204 enrolled
NCT00925548
2014-07-24
STRIDE
EMD Serono
Phase 3
Terminated
16 enrolled
6 charts